.jpg)
.jpg)
01 Apr, 2020
Halozyme Therapeutics Stock Up After Partnership with Roche
Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..
77.jpg)
Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint
Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..
.jpg)
Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials
Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..
Cara Therapeutic Shares Plummet
Shares of Cara Therapeutic Inc. (NASDAQ: CARA) fell 31 percent on Friday after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.Cara is a biopharmaceutical company that focuses on developing medications ..
@Newsletter
Sign Up for Weekly UpdatesOpt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!
No articles found.
.jpg){kind=small}
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).